 |
|
| Type | Public (NASDAQ: BCRX) |
|---|---|
| Founded | 1986 |
| Headquarters | Birmingham, Alabama, USA |
| Key people | Jon P. Stonehouse , President and Chief Executive Officer Stuart Grant, Chief Financial Officer |
| Industry | Healthcare |
| Products | Biotechnology |
| Revenue | $57.56 million USD (2008) |
| Employees | 80 (2008) |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Birmingham, Alabama.[1] The company focuses on cancer, autoimmune diseases, and viral infections.[1] The company's most notable function has been the production of the antiviral medication Peramivir, which was approved by the FDA for emergency use in the treatment of drug resistant influenza A virus subtype H1N1.[2]
Contents |
History
The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March of 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.[3]
Pipeline
- Forodesine HCl, investigational purine nucleoside phosphorylase (PNP) inhibitor for the treatment of T- and B-cell mediated disorders.
- BCX-4208/R3421, a second generation purine nucleoside phosphorylase inhibitor with applications in autoimmune diseases.
- Peramivir is an experimental antiviral drug being developed for the treatment of influenza.
References
- ^ a b "BioCryst Pharmaceuticals". BioCryst Pharmaceuticals. http://www.biocryst.com/companyoverview.htm. Retrieved 2009-04-29.
- ^ "Emergency use authorization for the unapproved drug Peramivir". U.S. Centers for Disease Control and Prevention. http://www.cdc.gov/h1n1flu/eua/EUA%20Peramivir%20Letter%20-%20Frieden.pdf. Retrieved 2009-10-28.
- ^ BioCryst named 29th fastest growing tech firm Birmingham Business Journal, November 26, 2008
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
